Oxytocin Therapy in Labor and Postpartum Care

Key Points

  • Oxytocin (Pitocin) is a uterotonic hormone that binds to myometrial receptors → increases intracellular calcium → stimulates uterine contractions
  • Three clinical uses: labor induction, labor augmentation, and postpartum hemorrhage (PPH) prevention/treatment
  • Induction dosing: Begin 0.5–2 milliunits/min IV; increase 1–2 milliunits/min every 15–30 minutes to achieve adequate contraction pattern
  • Tachysystole (>5 contractions in 10 minutes averaged over 30 minutes) → immediately reduce or stop oxytocin, reposition patient, and notify provider
  • FDA High-Alert Medication: Requires infusion pump administration; nurse continuously monitors FHR and uterine contraction pattern
  • Antidiuretic effect: Risk of water intoxication with prolonged high-dose infusion — monitor I&O and serum sodium

Mechanism of Action

Oxytocin binds to specific receptors in the myometrium (uterine smooth muscle), increasing intracellular calcium and causing muscle contraction. The response is dose- and receptor-dependent:

  • At term, the uterus has high oxytocin receptor density → strong contraction response
  • Preterm uterus has fewer receptors → weaker or unpredictable response
  • Oxytocin is released naturally in pulses during spontaneous labor; IV infusion mimics this effect artificially
  • Half-life: 3–5 minutes → uterine activity begins declining rapidly within minutes of stopping the infusion
  • Initial uterine response after starting infusion is often seen within 3 to 5 minutes

Clinical Indications

IndicationGoal
Labor inductionStimulate contractions when delivery is medically indicated before spontaneous onset
Labor augmentationEnhance inadequate contractions that fail to cause cervical dilation or fetal descent
PPH prevention10–20 units IM after delivery of anterior fetal shoulder or placenta to prevent postpartum hemorrhage
PPH treatmentIV oxytocin infusion/bolus as first-line uterotonic for uterine atony (IM option if IV access is not available)

Indications for Labor Induction (ACOG)

  • Oligohydramnios, postterm (>41 weeks), preeclampsia/hypertension
  • Diabetes mellitus, prelabor rupture of membranes (PROM)
  • Intrauterine growth restriction, nonreassuring fetal testing, fetal demise

Contraindications

  • Placenta previa, vasa previa, umbilical cord prolapse
  • Fetal malpresentation, cephalopelvic disproportion suspected
  • Previous classical cesarean birth, active herpes infection
  • Fetal distress, uterine hyperactivity/hypertonicity

Dosing Protocol

PhaseDoseAdministration
Induction/Augmentation start0.5–2 milliunits/minIV infusion pump
TitrationIncrease 1–2 milliunits/min every 15–30 minUntil adequate contraction pattern achieved
Maximum dosePer hospital protocol/provider order
PPH (IM route)10–20 units IMAfter delivery of anterior shoulder or placenta

Target contraction pattern: 3–5 contractions in 10 minutes, each lasting 40–60 seconds, with uterine relaxation between contractions allowing fetal oxygenation.

Bishop Score — Pre-Induction Cervical Assessment

A higher Bishop score predicts more successful induction. Score ≥6 indicates favorable cervix for induction.

ScoreDilationEffacementStationConsistencyPosition
0Closed0–30%−3FirmPosterior
11–2 cm40–50%−2MediumMid
23–4 cm60–70%−1, 0SoftAnterior
35–6 cm80%+1, +2

If Bishop score is low, cervical ripening agents (misoprostol, dinoprostone) are used before oxytocin.

Nursing Monitoring Priorities

Continuous monitoring during oxytocin infusion:

  • Uterine contraction pattern: Frequency, duration, strength — assess for tachysystole
  • Fetal heart rate (FHR): Monitor for late decelerations, variable decelerations, or prolonged decelerations indicating fetal compromise
  • Maternal vital signs: Blood pressure, pulse — hypotension possible
  • Intake and output: Oxytocin has antidiuretic properties → risk of water intoxication with prolonged use

Tachysystole Recognition and Management

Definition: More than 5 contractions in 10 minutes averaged over 30 minutes.

Tachysystole Response Protocol

Tachysystole reduces placental perfusion time → fetal hypoxia risk.

With nonreassuring FHR:

  1. Discontinue oxytocin immediately
  2. Reposition to lateral position
  3. Administer 500 mL IV bolus (unless contraindicated)
  4. Administer terbutaline 0.25 mg SQ (if ordered) to relax uterus

With reassuring FHR:

  1. Reposition (left or right lateral)
  2. Administer 500 mL IV bolus (if not fluid-restricted)
  3. Reduce or discontinue oxytocin per protocol if pattern does not resolve within 10 minutes

Adverse Effects

Adverse EffectMechanismNursing Action
Uterine tachysystoleExcessive stimulationReduce/stop oxytocin; see protocol above
Fetal distressInadequate fetal recovery between contractionsStop oxytocin; notify provider; prepare for delivery
Water intoxicationAntidiuretic effect at high dosesMonitor I&O, serum sodium; limit hypotonic fluids
Uterine ruptureRare — higher risk with prior uterine scarImmediate surgical emergency if suspected
Maternal hypotensionVasodilatory effectIV fluid; position change
Hypertensive/cerebrovascular events (rare)High-dose exposure in vulnerable patientsStop infusion and escalate emergently for severe headache, neurologic change, or abrupt BP rise

Clients with prior cesarean scar or prior myomectomy require heightened rupture surveillance during oxytocin titration because scarred myometrium tolerates overstimulation poorly.

Self-Check

  1. A nurse is administering oxytocin for labor augmentation. The tocometer shows 6 contractions in 10 minutes, and the FHR tracing shows late decelerations. What is the priority nursing action?
  2. A patient is receiving oxytocin at 20 milliunits/min for postpartum hemorrhage. Eight hours later, she has only 200 mL of urine output and is becoming confused. What complication should the nurse suspect, and what lab value should be checked?
  3. Why is a Bishop score assessed before initiating labor induction, and what score indicates a favorable cervix?